Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Fate Therapeutics, Inc. Banner

Fate Therapeutics, Inc.

FATE Stock Analysis

Page title

Section title

Breakdown
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Net Income
-25.883m-29.992m-33.462m-42.952m-66.598m-98.149m-173.387m-212.151m-281.721m-160.928m
Depreciation & Amortization
496.000K687.000K881.000K971.000K1.204M2.193M3.087M5.850M13.758M18.282M
Change in Working Capital
17.000K370.000K1.180M2.083M1.744M3.640M-12.773m2.098M-34.710m19.182M
Operating Cash Flow
-22.419m-18.397m-29.823m-36.905m-38.650m-83.175m-39.229m-162.870m-248.208m-132.263m
Capital Expenditure
-882.000k-1.498m-457.000k-1.725m-2.303m-7.395m-4.932m-50.704m-35.566m-6.153m
Free Cash Flow
-23.301m-19.895m-30.280m-38.630m-40.953m-90.570m-44.161m-213.574m-283.774m-138.416m
Debt Repayment
-1.750m-1.546m-7.689m-10.764m0.000-15.000m0.0000.0000.0000.000
Dividends Paid
0.0000.0000.0000.0000.0000.0000.0000.0000.0000.000
Common Stock Issued
142.000K36.729M28.849M43.206M137.270M162.406M282.348M453.129M9.207M85.000K
Common Stock Repurchased
0.000420.000K186.000K-193.000k2.693M2.522M0.0000.0000.0000.000
Net Change in Cash
-4.935m15.708M23.800M343.000K101.667M-90.700m82.533M-33.764m-72.250m-19.463m